EXCLUSIVE: Annovis Bio's Parkinson's Candidate Improves Speed, Motor Function Vs Placebo

Annovis Bio Inc (NYSE:ANVS) has announced efficacy data from the Phase 2 trial evaluating ANVS401 in Parkinson's disease (PD).
Data from 54 patients found that once-daily ANVS401 was superior to placebo in improving motor function.
ANVS401 was well-tolerated and safe, with no adverse effects related to treatment observed.
Related: Annovis Bio's Stock Trading Higher As Alzheimer's / Parkinson's Candidate Shows Cognitive Improvement.
Compared to the placebo group, statistically significant improvements in motor-dexterity, speed, and accuracy were observed in patients across doses of ANVS401, compared to placebo.
Further, patients taking ANVS401 5mg, 20mg, and 80mg also achieved statistically significant improvements from baseline on the same test.
Patients treated with ANVS401 10mg and 20mg once daily showed statistically significant improvements in several motor & non-motor functions compared to baseline.
Annovis is still analyzing certain biomarker data from the 54 PD patients.
The Company plans to request PD and Alzheimer's disease Meeting with FDA on the next steps in clinical development.
Annovis Bio will host an investor conference call today at 9 a.m. ET.
Related: Annovis' Alzheimer's/Parkinson's Candidate Protects Nerve Cells Against Ill Effects of Higher Neurotoxic Proteins.
Price Action: ANVS stock closed 4.17% lower at $30.35 on Monday.